Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1993-12-01
Target enrollment:
Participant gender:
Summary
Diabetes is associated with dyslipidaemia leading to generalized atherosclerosis,
cardiovascular disease (CVD) and nephropathy. Osteoprotegerin (OPG), a glycoprotein involved
in bone homeostasis, has been implicated in the pathogenesis leading up vessel calcification.
Furthermore, CVD in diabetics is associated with increased levels of OPG.
Aim: To investigate whether low dose simvastatin treatment (10-20 mg/day) reduces circulating
levels of OPG as well as adhesion molecules (VCAM-1; vascular cell adhesion molecule-1, ICAM;
intercellular cell adhesion molecule).